Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CFO Charles Schoch continued under a formal employment agreement with $468,600 annual salary.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Charles Schoch continued under a formal employment agreement with $468,600 annual salary
- Target annual bonus set at 40% of base salary
- Termination without cause or for good reason triggers nine months’ salary plus target bonus
- Time-based equity awards fully accelerate after qualifying termination around a change in control
- Agreement introduces defined severance and change-in-control obligations for Candel Therapeutics
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.